Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GHSR | Q92847 | 9/20 | 0.78 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.51 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.51 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.50 |
| ▸ | ATM | Q13315 | 1/20 | 0.49 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.48 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3631940 | 0.88 | GHSR (1.00) | GHSRKMT2AMEN1CYP1A2CYP3A4 | |
| SCHEMBL6081481 | 0.75 | GHSR (0.76) | GHSRKMT2AMEN1ALDH1A1PTGS2 | |
| SCHEMBL10107719 | 0.75 | ALDH2 (0.68) | KMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL17695174 | 0.71 | RAB9A (0.69) | KMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL3636891 | 0.71 | GHSR (0.75) | GHSRKMT2ACYP3A4CYP2D6CYP2C9 | |
| SCHEMBL29542280 | 0.70 | GAA (0.75) | GHSRKMT2AMEN1CYP1A2CYP3A4 | |
| SCHEMBL6080755 | 0.69 | GHSR (0.65) | GHSRKMT2AMEN1ALDH1A1PTGS2 | |
| SCHEMBL17241485 | 0.67 | RAB9A (0.57) | KMT2AMEN1ALDH1A1LMNA | |
| SCHEMBL18046667 | 0.67 | PTGS2 (0.61) | GHSRKMT2AMEN1CYP1A2CYP3A4 | |
| SCHEMBL8360215 | 0.67 | MMP13 (0.69) | KMT2AMEN1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060089398-A1 | Isoxazole carboxamide derivatives as ghrelin receptor modulators | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-04-27 | — | — | US | claimed |
| US-20100093638-A1 | TREAMENT FOR CHEMICAL SUBSTANCE ADDICTION | ABUNON AB (SE) | 2010-04-15 | — | — | US | disclosed |
| EP-2155227-A1 | NEW TREATMENT FOR CHEMICAL SUBSTANCE ADDICTION | Dickson, Suzanne L (SE) | 2010-02-24 | — | — | EP | disclosed |
| WO-2009020419-A1 | NEW TREATMENT FOR CHEMICAL SUBSTANCE ADDICTION | DICKSON SUZANNE L (SE) | 2009-02-12 | — | — | WO | disclosed |
| US-20060089398-A1 | Isoxazole carboxamide derivatives as ghrelin receptor modulators | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2006-04-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060089398-A1 | Isoxazole carboxamide derivatives as ghrelin receptor modulators | GPR119, GIPR, GLP1R | GHSR 5/4885KMT2A 1793/4885MEN1 3388/4885 |
| US-20100093638-A1 | TREAMENT FOR CHEMICAL SUBSTANCE ADDICTION | GHSR, GHRHR, TRHR | GHSR 1/4885KMT2A 1131/4885MEN1 3464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.